Background: Studies assessing thyroid hormones in metabolic syndrome (MetS) patients are contradictory. Also, the effect of MetS on thyroid function over time is not yet evaluated. This study investigated the prevalence and incidence of thyroid dysfunction (TD) as well as time trends of thyroid hormones in subjects with and without MetS, during a 10-year follow-up in Tehranian adult population. Methods: This is a prospective cohort study conducted in the framework of Tehran Thyroid Study on 5,786 subjects aged ≥20 years: 4,905 eligible participants entered the study after excluding those with corticosteroid or radioactive iodine use, pregnancy, thyrotropin (TSH) #x3c;0.1 and #x3e;10 mU/L, and missing data. Physical examinations were performed and serum concentrations of TSH, free thyroxine (FT4), thyroid peroxidase antibody (TPOAb), fasting plasma glucose, insulin, and lipid profile were assessed at baseline and 3-year intervals during the follow-up. MetS was defined according to the Joint Interim Statement Definition. Results: At baseline, there were no difference in median serum concentrations of FT4 and TSH between MetS and non-MetS group after adjusting for age, sex, BMI, smoking, and TPOAb positivity. Although there was higher risk of overt (42%) and subclinical hypothyroidism (16%) in MetS compared with non-MetS subjects, no significant difference was observed in adjusted ORs for any TD between 2 groups. There were also no significant differences in time trends of TSH, FT4, TPOAb positivity, and incidence rates of TDs between MetS and non-MetS groups during 10 years, after adjustment for age, sex, BMI, smoking status, and TPOAb positivity. Conclusion: MetS is not associated with thyroid hypofunction considering other important confounders such as age, sex, smoking, BMI, and TPOAb positivity. There is also no difference in the trend of thyroid hormones and incidence of TD between MetS and non-MetS subjects during a 10-year follow-up.
Eur Thyroid J

中文翻译：

---

甲状腺功能障碍面临代谢综合征的发病率：9 年随访的前瞻性比较研究

背景：评估代谢综合征 (MetS) 患者甲状腺激素的研究是相互矛盾的。此外，尚未评估 MetS 随时间推移对甲状腺功能的影响。本研究调查了在德黑兰成年人群中进行的 10 年随访期间，甲状腺功能障碍 (TD) 的患病率和发病率以及甲状腺激素在患有和未患有 MetS 的受试者中的时间趋势。方法：这是一项在德黑兰甲状腺研究框架内对 5,786 名年龄≥20 岁的受试者进行的前瞻性队列研究：在排除使用皮质类固醇或放射性碘、怀孕、促甲状腺激素 (TSH) #x3c;0.1 和 # x3e;10 mU/L，并且缺少数据。进行了体格检查，并在随访期间在基线和 3 年间隔评估了血清 TSH、游离甲状腺素 (FT4)、甲状腺过氧化物酶抗体 (TPOAb)、空腹血糖、胰岛素和血脂浓度。MetS 是根据联合临时声明定义定义的。结果：在基线时，在调整年龄、性别、BMI、吸烟和 TPOAb 阳性后，MetS 组和非 MetS 组之间 FT4 和 TSH 的中位血清浓度没有差异。尽管与非 MetS 受试者相比，MetS 的明显 (42%) 和亚临床甲状腺功能减退 (16%) 的风险更高，但两组之间任何 TD 的调整 OR 均未观察到显着差异。在调整年龄、性别、BMI、吸烟状况和 TPOAb 阳性后，10 年内 MetS 组和非 MetS 组的 TSH、FT4、TPOAb 阳性和 TDs 发生率的时间趋势也没有显着差异。结论：考虑到其他重要的混杂因素，如年龄、性别、吸烟、BMI 和 TPOAb 阳性，MetS 与甲状腺功能减退无关。在 10 年的随访期间，MetS 和非 MetS 受试者的甲状腺激素趋势和 TD 发生率也没有差异。
欧洲甲状腺杂志